<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3393">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588792</url>
  </required_header>
  <id_info>
    <org_study_id>FaST-1</org_study_id>
    <nct_id>NCT04588792</nct_id>
  </id_info>
  <brief_title>Furosemide as Supportive Therapy for COVID-19 Respiratory Failure</brief_title>
  <acronym>FaST-1</acronym>
  <official_title>Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19 - A Phase 2/3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind, placebo-controlled, randomized, parallel-group phase 2/3 study will study&#xD;
      the utility of nebulized furosemide for pulmonary inflammation in Intubated, mechanically&#xD;
      ventilated Patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double-blind, placebo-controlled, randomized, parallel-group phase 2/3 study will study&#xD;
      the utility of nebulized furosemide for pulmonary inflammation in Intubated, mechanically&#xD;
      ventilated Patients with COVID-19. The primary objective of the study is to establish the&#xD;
      efficacy and safety of nebulized furosemide for the treatment of respiratory failure&#xD;
      secondary to COVID-19 infection requiring invasive mechanical ventilation. The secondary&#xD;
      objective is to delineate the anti-inflammatory properties of furosemide in COVID- 19&#xD;
      patients using pharmacokinetic / pharmacodynamic analysis. The duration of the intervention&#xD;
      will be up to 28 days of intervention and patients will be followed till 60 days post&#xD;
      randomization. Participants will be randomized to either: Intervention Group: 40 mg&#xD;
      furosemide per dose, given by nebulization (4 mL of 10 mg/mL furosemide in 0.9% saline&#xD;
      solution) over 30 mins four times daily (Q6H) for up to 28 days OR Control Group: placebo,&#xD;
      given by nebulization (4 mL of 0.9% saline solution) over 30 mins four times daily for up to&#xD;
      28 days. One hundred and forty-four (144) evaluable patients will be enrolled in the Phase 2&#xD;
      study. If evidence of efficacy is found in the Phase 2 portion, these patients will be&#xD;
      enrolled in the Phase 3 study which aims to recruit 640 patients total (496 additional&#xD;
      patients to the phase 2 patients).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in pulmonary gas exchange</measure>
    <time_frame>Study Day 5</time_frame>
    <description>Improvement in oxygenation as determined by a standardized PaO2/FiO2 ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Requirement for mechanical ventilation</measure>
    <time_frame>Baseline to day 28</time_frame>
    <description>Number of ventilator-free days in the first 28 days after enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 60 post enrollment</time_frame>
    <description>All Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for supplemental oxygen</measure>
    <time_frame>To day 28 post enrollment</time_frame>
    <description>Number of days of alive and not requiring supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU Stay</measure>
    <time_frame>Up to 60 days post enrollment</time_frame>
    <description>Duration of ICU Stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>Up to 60 days post enrollment</time_frame>
    <description>Length of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 60 days post enrollment</time_frame>
    <description>Incidence of serious adverse events: incorporated as trial outcomes, defined a priori, in accordance with guidelines for academic ICU drug trials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhalation adverse events</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Adverse events during the nebulization of furosemide</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum levels of furosemide</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Serum levels of furosemide every 7 days until the completion of therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrolyte abnormalities</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Altered electrolytes on routine testing (frequency of hypokalemia (&lt; 3.0 meq/L), hypernatremia (&gt; 150 meq/L) or increased bicarbonate levels (&gt;30 meq/L) during the ICU stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine levels</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Levels of serum inflammatory cytokines (IL-6, IL-8, TNF-α) at baseline prior to first dose of intervention, day 7, and the completion of therapy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Covid19</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Inhaled Furosemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg furosemide per dose, given by nebulization (4 mL of 10 mg/mL furosemide in 0.9% saline solution) over 30 mins four times daily (Q6H) for up to 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebulized Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, given by nebulization (4 mL of 0.9% saline solution) over 30 mins four times daily (Q.I.D.) for up to 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Furosemide</intervention_name>
    <description>Furosemide administered by nebulization through the ventilator circuit</description>
    <arm_group_label>Inhaled Furosemide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Saline</intervention_name>
    <description>Saline administered by nebulization through the ventilator circuit</description>
    <arm_group_label>Nebulized Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with respiratory failure secondary to COVID-19 (SARS-CoV-2)&#xD;
             infection/pneumonia requiring invasive mechanical ventilation&#xD;
&#xD;
          2. Duration of mechanical ventilation less than 24 hours as measured from the time of&#xD;
             randomization&#xD;
&#xD;
          3. If female, must not be pregnant at the time of enrollment as determined by a serum or&#xD;
             urine pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of severe chronic pulmonary disease (e.g., preinfection requirement for&#xD;
             home oxygen therapy or presence of chronic hypercapnia (PaCO2&lt; 50 mm Hg); mild&#xD;
             -moderate disease is still eligible in the absence of chronic hypercapnia or need for&#xD;
             chronic oxygen therapy)&#xD;
&#xD;
          2. In the opinion of the PI, unlikely to survive for &gt;48 hours from time of enrollment&#xD;
&#xD;
          3. Treatment with anti-IL 6, anti-IL-6R antagonists, or with Janus kinase inhibitors&#xD;
             (JAKi) in the past 30 days or plans to receive during the study period&#xD;
&#xD;
          4. Known allergy to furosemide or sulfonamide agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Muscedere, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queens University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Muscedere, MD</last_name>
    <phone>6135496666</phone>
    <phone_ext>4642</phone_ext>
    <email>John.Muscedere@kingstonhsc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tracy Boyd</last_name>
    <phone>6135496666</phone>
    <email>Tracy.Boyd@kingstonhsc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oleksa Rewa, MD</last_name>
      <email>rewa@ualberta.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Osama Loubani, MD</last_name>
      <email>oloubani@dal.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Center</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Muscedere, MD</last_name>
      <phone>6135496666</phone>
      <phone_ext>4642</phone_ext>
      <email>John.Muscedere@kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Gordon Boyd, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dave Maslove, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Sibley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>HT Wand, MD</last_name>
      <email>ht.wang85@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Brennecke A, Villar L, Wang Z, Doyle LM, Meek A, Reed M, Barden C, Weaver DF. Is Inhaled Furosemide a Potential Therapeutic for COVID-19? Am J Med Sci. 2020 Sep;360(3):216-221. doi: 10.1016/j.amjms.2020.05.044. Epub 2020 Jun 1. Review.</citation>
    <PMID>32622469</PMID>
  </reference>
  <reference>
    <citation>Wang Z, Wang Y, Vilekar P, Yang SP, Gupta M, Oh MI, Meek A, Doyle L, Villar L, Brennecke A, Liyanage I, Reed M, Barden C, Weaver DF. Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide. PeerJ. 2020 Jul 7;8:e9533. doi: 10.7717/peerj.9533. eCollection 2020.</citation>
    <PMID>32704455</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. John Muscedere</investigator_full_name>
    <investigator_title>Professor of Medicine, Queen's University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

